A visionary doctor recognized a critical gap in the hand sanitization market - the need for an FDA-approved antimicrobial solution that could match alcohol's germ-killing efficacy while being gentle on skin. This insight sparked a determined journey through 60 different formulations to create what would become the only patented active ingredient approved by the FDA to kill germs as effectively as alcohol without harsh side effects.

The founder's medical expertise and unwavering commitment to improving public health drove over $1.5 million in rigorous testing and clinical studies. A GROUNDBREAKING independent university study on December 10, 2025, validated the breakthrough - proving this patented formula delivers alcohol-level antimicrobial protection while keeping hands soft and hydrated throughout repeated daily use. The valuable sought after trademark sets itself apart in a post covid market.

This established company has methodically built relationships with industry giants including McKesson Medical, Henry Schein, and Medline for distribution. Major retailers including CVS, Walgreens, Target, Costco, Office Depot, and Staples have approved the product line, positioning it for full market launch pending imminent FDA approval.

The story represents more than commercial success - it's about transforming public health. By enabling frequent sanitization without skin damage, this innovation could enhance infection prevention, reduce workplace and school absenteeism, and contribute to a healthier, more productive society.

This asset sale offers the opportunity to acquire the intellectual property and trademark of a patent-protected solution positioned to capture significant market share in the $3.6 billion sanitization industry. The next chapter awaits a visionary buyer ready to bring this doctor's life work to market and continue the mission of improving global wellness through innovative antimicrobial technology